Clinical Trials
55 trialsDRIVE-II
Sun Yat-sen University
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
M.D. Anderson Cancer Center
SCOTI
Rutgers, The State University of New Jersey
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
ERASE-CRC
Gruppo Oncologico del Nord-Ovest
ROMANCE - GOIM
Gruppo Oncologico Italia Meridionale
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
SHORT
Providence Health & Services
TRIFLUOX-DP
UNICANCER
TAS-102 NEC
Baylor Research Institute
RAK in GC
Chinese PLA General Hospital
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University
LONGBOARD
GERCOR - Multidisciplinary Oncology Cooperative Group
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
Jinan Central Hospital
Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer
Qingdao Central Hospital
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Ruijin Hospital
TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
The University of Hong Kong
BETWEEN
GERCOR - Multidisciplinary Oncology Cooperative Group
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sun Yat-sen University
TASLARC
Sun Yat-sen University
SOREGATT
UNICANCER
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
Rutgers, The State University of New Jersey
LOGICAN
UNICANCER
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Academic and Community Cancer Research United
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
First Affiliated Hospital of Wenzhou Medical University
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Academic and Community Cancer Research United
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Charite University, Berlin, Germany
TAS-102 and Anlotinib in ≥3 Lines mGC
Zhejiang University
BEV-TASIRI
Qilu Hospital of Shandong University
VELO
University of Campania Luigi Vanvitelli
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The First Affiliated Hospital with Nanjing Medical University
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Fudan University
TAS-102 in Treating Advanced Biliary Tract Cancers
Mayo Clinic
MOCHA
Sunnybrook Health Sciences Centre
Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
Sun Yat-sen University
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
UF-STO-LUNG-003
University of Florida
Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
University of Kansas Medical Center